

#3

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Box Sequence, Washington, D.C. 20231 on the date shown below.

Date: November 13, 2001

By:

Carol A. See

PATENT

Docket No. GC394C1-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)

David A. Estell)

Group Art Unit: 1652

Serial No.: 09/932,183)

Examiner: Unassigned

Filed: August 17, 2001)

For: Proteases from Gram-Positive
Organisms)STATEMENT OF SAMENESS

BOX SEQUENCE


Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(d), the computer readable copy of the sequence listing, and the paper copy submitted herewith in the above application are believed to be the same. The present submission contains no new matter relative to the application as originally filed.

Respectfully submitted,

Date: Nov 13, 2001


Victoria L. Boyd
Registration No. 43,510Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94304-1013
Tel: 650-846-7615
Fax: 650-845-6504

GC394C1-US sameness




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/932,183	08/17/2001	David A. Estell	GC394C1-US

CONFIRMATION NO. 5103

FORMALITIES LETTER



0000000005591547

Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94034

Date Mailed: 09/21/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 18, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

04/26/2002

14:00

GENENCOR LEGAL → 17033084556

NO. 382 0026

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE